.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,410,550

« Back to Dashboard

Claims for Patent: 6,410,550

Title: Aryl fused azapolycyclic compounds
Abstract:Compounds of the formula ##STR1## and their pharmaceutically acceptable salts, wherein R.sup.1, R.sup.2, and R.sup.3 are defined as in the specification, intermediates in the synthesis of such compounds. pharmaceutical compositions containing such compounds and methods of using such compounds, in the treatment of neurological and psychological disorders.
Inventor(s): Coe; Jotham Wadsworth (Niantic, CT), Brooks; Paige Roanne Palmer (North Stonington, CT)
Assignee: Pfizer INC (New York, NY)
Application Number:09/402,010
Patent Claims: 1. A compound of the formula ##STR26##

R.sup.1 is hydrogen, (C.sub.1 -C.sub.6)alkyl, unconjugate (C.sub.3 -C.sub.6)alkenyl, XC(.dbd.O)R.sup.13, benzyl or --CH.sub.2 CH.sub.2 --O--(C.sub.1 -C.sub.4)alkyl;

R.sup.2 and R.sup.3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the nonfused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo rings shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents that are selected, independently, from (C.sub.1 -C.sub.6) alkyl optionally substituted with from one to seven fluorine atoms; (C.sub.1 -C.sub.6)alkoxy optionally substituted with from one to seven fluorine atoms; nitro, cyano, halo, (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, hydroxy, amino, (C.sub.1 -C.sub.6)alkylamino and ((C.sub.1 -C.sub.6)alkyl).sub.2 amino, --CO.sub.2 R.sup.4, --CONR.sup.5 R.sup.6, --SO.sub.2 NR.sup.7 R.sup.8, --C(.dbd.O)R.sup.13 and --XC(.dbd.O)R.sup.13 ;

wherein each R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.13 is selected, independently, from hydrogen and (C.sub.1 -C.sub.6) alkyl, or R.sup.5 and R.sup.6, or R.sup.7 and R.sup.8 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, --N--(C.sub.1 -C.sub.6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and

each X is, independently, (C.sub.1 -C.sub.6)alkylene;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein R.sup.2 and R.sup.3, together with the benzo of formula I, form a bicyclic ring system selected from the following: ##STR27##

wherein R.sup.10 and R.sup.17 are selected, independently, from (C.sub.1 -C.sub.6) alkyl optionally substituted with from one to seven fluorine atoms; (C.sub.1 -C.sub.6) alkoxy optionally substituted with from one to seven fluorine atoms; (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, hydroxy, amino, (C.sub.1 -C.sub.6)alkylamino and ((C.sub.1 -C.sub.6)alkyl).sub.2 amino, --CO.sub.2 R.sup.4, --CONR.sup.5 R.sup.6, --SO.sub.2 NR.sup.7 R.sup.8, --C(.dbd.O)R.sup.13 and --XC(.dbd.O)R.sup.13 and wherein R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.13 are as defined in claim 1.

3. A compound according to claim 1 selected from the group consisting of:

5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

7-methyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

6-methyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

7-propyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

7-butyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

6-methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

7-neopentyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

6-methyl-7-neopentyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,6,8-tetraene;

and pharmaceutically acceptable salts thereof.

4. A compound according to claim 1 which is:

6-methyl-5-thia-7,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,6,8-tetraene;

or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 1 which is:

6-methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 1 which is:

6,7-dimethyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,5,8-tetraene;

or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 1 which is:

6,7dimethyl-5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]hexadeca-2(11),3,5,7,9-pentaene;

or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 1 which is:

5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]hexadeca-2(11),3,5,7,9-pentaene;

or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 1 which is:

14-methyl-5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9 ]hexadeca-2(11),3,5,7,9-pentaene;

or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 1 which is:

5-oxa-7,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2(10),3,6,8-tetraene;

or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 1 which is:

7-methyl-5-oxa-6,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8 ]pentadeca-2,4(8),6,9-tetraene;

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising an amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

13. A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.

14. A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

15. A compound of the formula (I') ##STR28##

wherein

R.sup.2 and R.sup.3, together with the carbons to which they are attached, form a four to seven membered monocyclic, or ten to fourteen membered bicyclic, carbocyclic ring that can be saturated or unsaturated, wherein from one to three of the nonfused carbon atoms of said monocyclic rings, and from one to five of the carbon atoms of said bicyclic rings that are not part of the benzo ring shown in formula I, may optionally and independently be replaced by a nitrogen, oxygen or sulfur, and wherein said monocyclic and bicyclic rings may optionally be substituted with one or more substituents that are selected, independently, from (C.sub.1 -C.sub.6) alkyl optionally substituted with from one to seven fluorine atoms; (C.sub.1 -C.sub.6)alkoxy optionally substituted with from one to seven fluorine atoms; nitro, cyano, halo, (C.sub.2 -C.sub.6)alkenyl, (C.sub.2 -C.sub.6)alkynyl, hydroxy, amino, (C.sub.1 -C.sub.6)alkylamino and ((C.sub.1 -C.sub.6)alkyl).sub.2 amino, --CO.sub.2 R.sup.4, --CONR.sup.5 R.sup.6, --SO.sub.2 NR.sup.7 R.sup.8, --C(.dbd.O)R.sup.13 and --XC(.dbd.O)R.sup.13 ;

wherein each R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.13 is selected, independently, from hydrogen and (C.sub.1 -C.sub.6) alkyl, or R.sup.5 and R.sup.6, or R.sup.7 and R.sup.8 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, --N--(C.sub.1 -C.sub.6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; and

each X is, independently, (C.sub.1 -C.sub.6)alkylene;

and P' is COOR.sup.16 wherein R.sup.16 is allyl, 2,2,2-trichloroethyl or (C.sub.1 -C.sub.6)alkyl; --C(.dbd.O)NR.sup.5 R.sup.6 wherein R.sup.5 and R.sup.6 are selected, independently, from hydrogen and (C.sub.1 -C.sub.6) alkyl, or R.sup.5 and R.sup.6 together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, morpholine, azetidine, piperazine, --N--(C.sub.1 -C.sub.6)alkylpiperazine or thiomorpholine ring, or a thiomorpholine ring wherein the ring sulfur is replaced with a sulfoxide or sulfone; --C(.dbd.O)H, --C(.dbd.O)(C.sub.1 -C.sub.6)alkyl wherein the alkyl moiety may optionally be substituted with from 1 to 3 halo atoms; benzyl, or t-butoxycarbonyl (t-Boc).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc